AZD5462

Phase 2Small molecule

AstraZeneca

AZD5462 is one of 24 small molecule programs targeting Heart Failure. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Chronic Heart FailureCompleted

Heart FailurePhase 2

Active, not recruiting

Chronic Heart FailurePhase 2

Completed

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Brethine

Sanofi

Preclinical

1 2

Amidate

Pfizer

Preclinical

1 3

LCZ696

Novartis

Preclinical

15 4

Zemplar

AbbVie

Preclinical

—5

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 6

Xifaxan

SSalix

Preclinical

2 7

Zoloft

VViatris Specialty LLC

Preclinical

2 8

AZD5462

AstraZeneca

Phase 2

1 9

Coumadin

AAbbott

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Absorption1 trial

A Study Designed to Assess the Mass Balance Recovery, Absorption, Metabolism, Excretion of [14C]AZD5462 and the Absolute Bioavailability of AZD5462

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06989983·8 enrolled

Midazolam1 trial

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05395117·32 enrolled

Heart Failure1 trial

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT06639087·8 enrolled

Renal Impairment1 trial

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT06661733·16 enrolled

Tics1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04994106·98 enrolled

2 more indications

Chronic Heart Failure1 trial

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT06299826·375 enrolled

Unspecified1 trial

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05512806·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for AZD5462. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5462 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5462. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD5462

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Absorption1 trial

Midazolam1 trial

Heart Failure1 trial

Renal Impairment1 trial

Tics1 trial

Chronic Heart Failure1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News